Skip to main content
Clinical Trials/NCT04780386
NCT04780386
Completed
Phase 1

A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1805 and Coadministration of NVP-1805-R1 With NVP-1805-R2 in Healthy Male Volunteers

NVP Healthcare1 site in 1 country58 target enrollmentAugust 29, 2020

Overview

Phase
Phase 1
Intervention
NVP-1805
Conditions
Healthy
Sponsor
NVP Healthcare
Enrollment
58
Locations
1
Primary Endpoint
Pharmacokinetics of plasma: AUClast
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The purpose of this study is to compare the pharmacokinetics of NVP-1805 and coadministration of NVP-1805-R1 with NVP-1805-R2.

Detailed Description

pharmacokinetics and safety of NVP-1805 compared to coadministration of NVP-1805-R1 with NVP-1805-R2

Registry
clinicaltrials.gov
Start Date
August 29, 2020
End Date
February 16, 2021
Last Updated
5 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
NVP Healthcare
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy adult subjects who signed informed consent
  • BMI of \>18.0 kg/㎡ and \<30.0 kg/㎡ subject, weight more than 50kg(45 kg or more for woman)

Exclusion Criteria

  • Subjects participated in another clinical trial within 6 months prior to administration of the study drug
  • Inadequate subject for the clinical trial by the investigator's decision
  • Subjects participated in another clinical trial within 6 months prior to administration of the study drug

Arms & Interventions

NVP-1805

NVP-1805

Intervention: NVP-1805

NVP-1805-R1 and NVP-1805-R2

coadministration of NVP-1805-R1 and NVP-1805-R2

Intervention: NVP-1805-R1and NVP-1805-R2

Outcomes

Primary Outcomes

Pharmacokinetics of plasma: AUClast

Time Frame: 0hours - 72hours

Pharmacokinetics of plasma: Cmax

Time Frame: 0hours - 72hours

Study Sites (1)

Loading locations...

Similar Trials